These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16929495)

  • 1. Do we need a different strategy for HPV screening and vaccination in East Asia?
    Miura S; Matsumoto K; Oki A; Satoh T; Tsunoda H; Yasugi T; Taketani Y; Yoshikawa H
    Int J Cancer; 2006 Dec; 119(11):2713-5. PubMed ID: 16929495
    [No Abstract]   [Full Text] [Related]  

  • 2. The rationale for implementation of HPV testing in routine cervical screening in Romania.
    Iancu LS; Ursu RG
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):293-6. PubMed ID: 24340506
    [No Abstract]   [Full Text] [Related]  

  • 3. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
    Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
    Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV testing could cut cervical cancers by a third, finds study.
    Kmietowicz Z
    BMJ; 2013 Jun; 346():f3888. PubMed ID: 23771041
    [No Abstract]   [Full Text] [Related]  

  • 6. A summary of the 25th International Papillomavirus Conference 2009: vaccines, screening, epidemiology and therapeutics.
    Nicol AF; Nuovo GJ; Dillner J
    J Clin Virol; 2010 Mar; 47(3):208-15. PubMed ID: 20080439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV-vaccine and screening programs: the new era of global prevention.
    Mariani L
    J Prev Med Hyg; 2009 Jun; 50(2):90-5. PubMed ID: 20099438
    [No Abstract]   [Full Text] [Related]  

  • 8. Is viral status needed before vaccination?
    Wright TC; Bosch FX
    Vaccine; 2008 Mar; 26 Suppl 1():A12-5. PubMed ID: 18642458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
    Syrjänen K
    Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries.
    Simonella L; Canfell K
    Vaccine; 2015 Jan; 33(1):34-51. PubMed ID: 25171843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
    El-Zein M; Richardson L; Franco EL
    J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-vaccination prevalence and genotype distribution of human papillomavirus infection among women from urban Tunis: a cross-sectional study.
    Guettiti H; Ennaifer E; Attia L; Chelly D; Alaya NB; Aissa RB; Laassili T; Boubaker S
    Asian Pac J Cancer Prev; 2014; 15(21):9361-5. PubMed ID: 25422225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput monitoring of human papillomavirus type distribution.
    Söderlund-Strand A; Dillner J
    Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):242-50. PubMed ID: 23221127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic HPV vaccination: a major breakthrough in the fight against cervical cancer?
    Saleem A; Tristram A; Fiander A; Hibbitts S
    Minerva Med; 2009 Dec; 100(6):503-23. PubMed ID: 20010484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of human papillomavirus vaccination depends on effective vaccination strategy.
    Lehtinen M; Paavonen J
    Int J Cancer; 2009 Sep; 125(6):1490-1. PubMed ID: 19507251
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey.
    Tanton C; Soldan K; Beddows S; Mercer CH; Waller J; Field N; Clifton S; Copas AJ; Panwar K; Manyenga P; da Silva F; Wellings K; Ison CA; Johnson AM; Sonnenberg P
    Cancer Epidemiol Biomarkers Prev; 2015 May; 24(5):842-53. PubMed ID: 25737331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics.
    Zejnullahu Raçi P; Hošnjak L; Poljak M; Lepej SŽ; Vince A
    Ginekol Pol; 2018; 89(9):485-494. PubMed ID: 30318575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.